Search

Jacobson, C C, and A B Kimball. 2004. “Rethinking the Psoriasis Area and Severity Index: The Impact of Area Should Be Increased.”. The British Journal of Dermatology 151 (2): 381-7.

Papp, Kim A, Bruce Strober, Matthias Augustin, Steve Calabro, Anil Londhe, Marc Chevrier, and PSOLAR investigators and Steering Committee. 2012. “PSOLAR: Design, Utility, and Preliminary Results of a Prospective, International, Disease-Based Registry of Patients With Psoriasis Who Are Receiving, or Are Candidates For, Conventional Systemic Treatments or Biologic Agents.”. Journal of Drugs in Dermatology : JDD 11 (10): 1210-7.

Alora-Palli, Maria B, Alexis C Perkins, Alicia Van Cott, and Alexandra B Kimball. 2010. “Efficacy and Tolerability of a Cosmetically Acceptable Coal Tar Solution in the Treatment of Moderate Plaque Psoriasis: A Controlled Comparison With Calcipotriene (calcipotriol) Cream.”. American Journal of Clinical Dermatology 11 (4): 275-83.

Kimball, Alexa B, and Thomas S Kupper. 2008. “Future Perspectives/Quo Vadis Psoriasis Treatment? Immunology, Pharmacogenomics, and Epidemiology.”. Clinics in Dermatology 26 (5): 554-61.

Menter, Alan, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, et al. 2008. “Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial.”. Journal of the American Academy of Dermatology 58 (1): 106-15.

Weiss, Stefan C, Wingfield Rehmus, and Alexa B Kimball. 2006. “An Assessment of the Cost-Utility of Therapy for Psoriasis.”. Therapeutics and Clinical Risk Management 2 (3): 325-8.

Feldman, Steven R, Alexa Boer Kimball, Gerald G Krueger, Michael Woolley, Deepa Lalla, and Angelika Jahreis. 2005. “Etanercept Improves the Health-Related Quality of Life of Patients With Psoriasis: Results of a Phase III Randomized Clinical Trial.”. Journal of the American Academy of Dermatology 53 (5): 887-9.

Reid, David C, and Alexa B Kimball. 2005. “Clobetasol Propionate Foam in the Treatment of Psoriasis.”. Expert Opinion on Pharmacotherapy 6 (10): 1735-40.

Kimball, A B, K B Gordon, S Fakharzadeh, N Yeilding, P O Szapary, B Schenkel, C Guzzo, S Li, and K A Papp. 2012. “Long-Term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis: Results from the PHOENIX 1 Trial through up to 3 Years.”. The British Journal of Dermatology 166 (4): 861-72.

Langley, Richard G, Steven R Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B Gordon, and Alexa B Kimball. 2010. “Ustekinumab Significantly Improves Symptoms of Anxiety, Depression, and Skin-Related Quality of Life in Patients With Moderate-to-Severe Psoriasis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Trial.”. Journal of the American Academy of Dermatology 63 (3): 457-65.